Overview

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

Status:
Recruiting

Trial end date:
2021-10-18

Target enrollment:

Participant gender:

Summary

This Phase III study will compare the efficacy and tolerability of a Fixed Dose Combination of Etodolac + Cyclobenzaprine versus the isolated drugs in postoperative pain control after impacted third molar extraction.

Phase:

Phase 3

Details

Lead Sponsor:

Apsen Farmaceutica S.A.

Treatments:

Amitriptyline
Cyclobenzaprine
Etodolac